Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Sep;207(2):275-282.
doi: 10.1007/s10549-024-07417-4. Epub 2024 Jul 5.

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Jessica Mezzanotte-Sharpe  1 , Anne ONeill  2 , Ingrid A Mayer  1 , Carlos L Arteaga  3 , Ximing J Yang  4 , Lynne I Wagner  5 , David Cella  4 , Neal J Meropol  6 , R Katherine Alpaugh  7 , Thomas J Saphner  8 , Robert E Swaney  9 , Karen L Hoelzer  10 , William J Gradishar  4 , Vandana G Abramson  1 , P Kothai Sundaram  11 , Shamim Z Jilani  12 , Edith A Perez  13 , Nancy U Lin  2 , Mohammad Jahanzeb  14 , Antonio C Wolff  15 , George W Sledge  16 , Sonya A Reid  17
Affiliations
Clinical Trial

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Jessica Mezzanotte-Sharpe et al. Breast Cancer Res Treat. 2024 Sep.

Abstract

Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC.

Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43-1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61-1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab.

Conclusions: In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time.

Clinical trial information: NCT00520975.

Keywords: Bevacizumab; Breast cancer; Chemotherapy; Trastuzumab.

PubMed Disclaimer

Conflict of interest statement

JMS, AON, TJS, WJG, EAP, and ACW have no conflicts of interest related to this project. CLA has served as scientific advisor to Novartis, Lilly, Merck, Immunomedics, Daiichi Sankyo, AstraZeneca, PUMA Biotechnology, TAIHO Oncology, OrigiMed, Arvinas, Sanofi, and the Susan G. Komen Foundation. He has received grant support from Pfizer, Lilly, and Takeda. NJM is an employee of Flatiron Health, Inc. an independent member of the Roche group, and reports stock ownership in Roche. VGA has served as a scientific advisor for GuardantHealth and Astra Zeneca and has research funding support from Genetech, Bayer, and GuardantHealth. NUL declares consulting honorarium from Seagen, Daichii-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., Eisai; travel support from Olema Pharmaceuticals; research support (to institution) from Genentech, Zion Pharmaceuticals (as part of GNE), Pfizer, Seagen, Merck, Olema Pharmaceuticals, AstraZeneca; royalties from Up To Date. SAR has served as a consultant for Daiichi-Sankyo, Astra Zeneca, Novartis, and Gilead.

Figures

Fig. 1
Fig. 1
Study consort diagram
Fig. 2
Fig. 2
PFS and OS. A Median PFS was 11.1 months in the PLAC (placebo) arm and 13.8 months in the BEV (bevacizumab) arm, p = 0.24. B Median OS was 49.1 months in the PLAC arm and 63 months in the BEV arm (figure truncated at 60 months), p = 0.75. CI = confidence interval
See this image and copyright information in PMC

Update of

References

    1. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676 10.1056/NEJMoa072113 - DOI - PubMed
    1. Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E et al (2012) Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol 2012:417673 10.1155/2012/417673 - DOI - PMC - PubMed
    1. Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K et al (2004) Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 40(1):33–42 10.1016/S0959-8049(03)00673-7 - DOI - PubMed
    1. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151(6):1523–1530 - PMC - PubMed
    1. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D (2002) ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94(11):2855–2861 10.1002/cncr.10553 - DOI - PubMed

Publication types

MeSH terms

Associated data